We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
- Authors
Jimeno, Antonio; Grávalos, Cristina; Escudero, Pilar; Sevilla, Isabel; Vega-Villegas, M.; Alonso, Vicente; Juez, Ignacio; García-Carbonero, Rocío; Bovio, Humberto; Colomer, Ramón; Cortés-Funes, Hernán
- Abstract
The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC). Patients with advanced CRC were treated with gefitinib administered daily for 21 days and capecitabine administered twice daily for 14 days of a 21-day cycle. The dose levels of gefitinib (mg) and capecitabine (mg/m2 bid) assessed were 250/1000 and 250/ 1250. An expanded cohort was enrolled at the MTD to better characterise toxicity and efficacy. A total of 32 previously treated patients were accrued. In the phase I part 10 subjects were treated, with one dose-limiting toxicity. Overall 26 patients were treated at the MTD of the combination, which was gefitinib 250 mg/day and capecitabine 1250 mg/m2 twice daily. The most frequent treatment-related adverse events included asthenia, diarrhoea, nausea, rash and anorexia. The incidence profile was very similar in phases I and II. No objective responses were documented but 53% of the patients achieved stable disease as best response to therapy. Capecitabine 1250 mg/m2 twice daily 14 of 21 days and gefitinib at 250 mg/day can be safely administered in combination. The combination is relatively well tolerated. There were no objective responses, although an interesting stabilisation rate was documented, in previously treated advanced CRC patients.
- Publication
Clinical & Translational Oncology, 2008, Vol 10, Issue 1, p52
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-008-0153-5